Litigation Details for Belcher Pharmaceuticals, LLC v. Hospira, Inc. (D. Del. 2019)

Belcher Pharmaceuticals, LLC v. Hospira, Inc. (D. Del. 2019)

Docket		Date Filed	2019-10-03
Court	District Court, D. Delaware	Date Terminated	2022-08-10
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	HOSPIRA, INC.
Patents	10,004,700; 10,039,728
Attorneys	John C. Phillips , Jr.
Firms	Dorsey & Whitney (Delaware) LLP
Link to Docket	External link to docket

Details for Belcher Pharmaceuticals, LLC v. Hospira, Inc. (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-10-03				External link to document
2019-10-03	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,004,700 ; 10,039,728. (kmd…2019 5 November 2019 1:19-cv-01854 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

# Belcher Pharmaceuticals v. Hospira Patent Litigation: Epinephrine Injection Case 1:19-cv-01854

Last updated: September 2, 2026

Belcher Pharmaceuticals, LLC lost its Hatch-Waxman patent litigation against Hospira, Inc. over Hospira’s generic epinephrine injection. The U.S. District Court for the District of Delaware held that Belcher’s U.S. Patent No. 9,283,197 was invalid for obviousness and unenforceable for inequitable conduct. The Federal Circuit affirmed in 2021. The decision removed the principal patent barrier to Hospira’s abbreviated new drug application, or ANDA, for epinephrine injection and materially weakened Belcher’s exclusivity position for the product.[1][2]

What was Belcher Pharmaceuticals v. Hospira, Inc. about?

The case concerned an epinephrine pharmaceutical composition with a specified pH range and sulfite content. Belcher’s patent claimed formulations designed to improve the stability of epinephrine while maintaining a commercially usable injectable product.

Hospira submitted an ANDA seeking FDA approval to market a generic epinephrine injection. Belcher filed suit under the Hatch-Waxman Act after receiving notice of Hospira’s Paragraph IV certification that the relevant patent was invalid, unenforceable, or would not be infringed.

Item	Details
Case	Belcher Pharmaceuticals, LLC v. Hospira, Inc.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:19-cv-01854
Federal Circuit appeal	No. 21-1798
Patent at issue	U.S. Patent No. 9,283,197
Patent title	Pharmaceutical compositions of epinephrine
Plaintiff	Belcher Pharmaceuticals, LLC
Defendant	Hospira, Inc.
Technology	Epinephrine injectable formulations
Primary statutory issues	35 U.S.C. §§ 102, 103, 112, 271(e)(2), and inequitable conduct
Final appellate result	District court judgment affirmed

What patent protected Belcher’s epinephrine product?

U.S. Patent No. 9,283,197 covered pharmaceutical compositions containing epinephrine, a sulfite, and a solvent, with the composition maintained within a defined pH range. The asserted claims focused on an epinephrine formulation having a pH of approximately 2.8 to 3.3.[3]

The patent’s commercial relevance came from the difficulty of maintaining epinephrine stability in an injectable formulation. Epinephrine is susceptible to degradation, including oxidation and racemization. Sulfite compounds can act as antioxidants, but formulation pH, preservative concentration, oxygen exposure, and storage conditions affect product quality.

The patent did not broadly cover epinephrine as an active ingredient. Its scope depended on the claimed combination of:

• Epinephrine or an acceptable salt;
• A sulfite component;
• A solvent or injectable vehicle; and
• A specific pH range.

The asserted patent therefore operated as a formulation patent rather than a composition-of-matter patent covering epinephrine itself.

What formulation characteristics were at issue?

The central technical issue was whether the claimed pH range represented a patentable formulation advance over information already available to the Food and Drug Administration and the pharmaceutical industry.

The district court found that the claimed pH range was not sufficiently inventive when viewed against the prior art and the FDA’s communications concerning epinephrine formulation development. The court also found that Belcher’s failure to disclose material information to the U.S. Patent and Trademark Office supported an inequitable-conduct finding.[1]

Why did Belcher sue Hospira?

Hospira’s ANDA filing constituted an artificial act of infringement under 35 U.S.C. § 271(e)(2). Belcher’s lawsuit triggered the statutory stay of FDA approval associated with a Paragraph IV challenge.

Belcher sought to prevent Hospira from obtaining approval and commercializing its generic epinephrine product before expiration of the ’197 patent. The litigation presented the standard Hatch-Waxman questions:

1. Whether Hospira’s ANDA product would infringe the asserted claims;
2. Whether the claims were invalid for obviousness or lack of written description;
3. Whether the patent was enforceable; and
4. Whether Belcher could obtain an injunction or other relief against generic entry.

Because the district court found the patent invalid and unenforceable, the court did not need to impose a product-specific injunction against Hospira.

When did the Belcher v. Hospira litigation begin?

The litigation was filed in the District of Delaware in 2019 under Civil Action No. 1:19-cv-01854. The case proceeded as an ANDA patent action involving Belcher’s epinephrine product and Hospira’s proposed generic.

The key procedural sequence was:

Date	Event
2019	Belcher filed the Hatch-Waxman action against Hospira
2020-2021	District court conducted claim-construction, discovery, and trial proceedings
2021	District court entered judgment against Belcher on validity and enforceability
2021	Belcher appealed to the Federal Circuit
Aug. 2021	Federal Circuit affirmed the district court’s judgment
After appellate affirmance	The patent could no longer provide an enforceable barrier to Hospira’s ANDA product

The Federal Circuit decision is reported at 11 F.4th 1345.[2]

Why did the court find the patent invalid for obviousness?

The court found that the claimed formulation would have been obvious to a person of ordinary skill in the art based on the prior art and the technical information available before the patent’s effective filing date.

The obviousness analysis focused on the relationship between:

• Known epinephrine formulations;
• Known use of sulfites as stabilizing agents;
• Known pH ranges for epinephrine products;
• FDA communications concerning acceptable formulation parameters; and
• Routine optimization of pH and excipient concentrations.

The court rejected Belcher’s position that the claimed pH range represented a non-obvious discovery. The evidence showed that skilled formulators would have had reason to evaluate the claimed range and a reasonable expectation that the resulting formulation could be used in an injectable epinephrine product.[1]

The Federal Circuit affirmed the obviousness judgment. The appellate decision treated the district court’s findings as supported by the record and did not identify reversible error in the court’s analysis.[2]

Did unexpected results save the patent?

No. Belcher argued that its formulation produced improved stability and other technical advantages. The court did not find those results sufficient to overcome the strong obviousness showing.

Unexpected results can support non-obviousness when they are commensurate with the scope of the claims and demonstrate a meaningful technical difference over the prior art. In this case, the court determined that Belcher’s evidence did not establish a sufficient nexus between the claimed formulation and an unexpected advantage that would overcome the prior-art combination.

The case illustrates the risk associated with narrow formulation patents that rely on optimization of known variables. A defined pH range may be patentable when the range produces an unexpected technical effect, but routine selection within an established formulation space is vulnerable under Section 103.

Why did the court find inequitable conduct?

The court held that the ’197 patent was unenforceable because of inequitable conduct. The finding centered on material information that was not disclosed to the USPTO during patent prosecution.

The Federal Circuit affirmed the inequitable-conduct ruling. The appellate court accepted the district court’s finding that the withheld information was material and that the relevant individual possessed the specific intent to deceive the USPTO.[2]

The case is significant because it involved information arising from FDA interactions. FDA communications can be relevant to patentability when they contain technical information, admissions, product-development constraints, or evidence concerning the state of the art. Their regulatory origin does not eliminate their potential materiality in patent prosecution.

The decision also reinforces the need for patent applicants to evaluate information received from:

• FDA review teams;
• Pre-approval meetings;
• Chemistry, manufacturing, and controls correspondence;
• Deficiency letters;
• Product-development consultants; and
• Regulatory submissions involving related formulations.

The inequitable-conduct finding independently eliminated enforcement of the patent, even apart from the obviousness judgment.

What was the Orange Book status of the Belcher patent?

The ’197 patent was associated with Belcher’s epinephrine product and was asserted in the ANDA litigation. The Orange Book listing gave Belcher a statutory basis to sue Hospira after Hospira submitted its Paragraph IV certification.[4]

The litigation demonstrates the commercial vulnerability of Orange Book-listed formulation patents. Listing creates a procedural mechanism for enforcing the patent against an ANDA applicant, but it does not establish patent validity or enforceability. Once the court invalidated and rendered the patent unenforceable, the listing no longer provided an effective litigation barrier.

A listing can still affect the regulatory timeline while litigation is pending because a timely Paragraph IV suit can trigger a 30-month stay of FDA approval. The stay does not survive as a substantive patent right after the patent is invalidated or held unenforceable.

Was Hospira’s challenge a Paragraph IV challenge?

Yes. Hospira’s ANDA challenge proceeded under the Paragraph IV framework. Hospira represented that the listed patent was invalid, unenforceable, or not infringed.

The Paragraph IV pathway allowed Hospira to seek FDA approval before the patent’s nominal expiration date. Belcher’s lawsuit initiated the patent dispute, but the resulting judgment favored Hospira.

A successful Paragraph IV defense can produce several commercial effects:

• Removal of the patent-based approval barrier;
• Earlier FDA approval than a Paragraph III filing would permit;
• Potential 180-day exclusivity for the first qualifying ANDA applicant, depending on the regulatory record; and
• Increased pressure on the branded product’s pricing and market share.

The public litigation outcome does not by itself establish whether Hospira received first-filer exclusivity or exactly when the product entered the market. Those issues depend on FDA approval records and the ANDA’s regulatory status.

Did the case involve biosimilar risk?

No. Epinephrine is a small-molecule active pharmaceutical ingredient, not a biologic. Hospira’s application proceeded through the ANDA pathway rather than the biosimilar pathway under the Biologics Price Competition and Innovation Act.

The relevant competitive threat was generic substitution, not biosimilar competition. The case involved:

• Hatch-Waxman litigation;
• An ANDA;
• A Paragraph IV certification;
• Small-molecule formulation patents; and
• Potential generic epinephrine entry.

Biosimilar concepts such as reference-product exclusivity, interchangeability, and the 351(k) pathway do not govern this dispute.

What was the litigation outcome?

The district court entered judgment that the asserted claims of the ’197 patent were invalid for obviousness and unenforceable for inequitable conduct. The Federal Circuit affirmed.

Issue	Result
Infringement	No enforceable patent relief available
Validity	Patent claims held invalid for obviousness
Enforceability	Patent held unenforceable for inequitable conduct
FDA approval barrier	Removed by the judgment
Injunction against Hospira	Not available after invalidity and unenforceability findings
Federal Circuit review	Judgment affirmed
Settlement	The reported appellate disposition was an affirmance, not a settlement

The Federal Circuit’s affirmance made the adverse judgment controlling in the dispute between Belcher and Hospira. The case did not produce a damages award for Belcher.

How strong was Belcher’s patent estate after the decision?

Belcher’s patent position for the litigated epinephrine formulation was weak after the decision because the principal asserted patent was both invalid and unenforceable.

The risk assessment is summarized below:

Patent-estate factor	Assessment
Core product patent	Defeated in litigation
Formulation protection	Reduced substantially
Method-of-use protection	Not the primary basis of the case
Manufacturing protection	Not established as a barrier in the reported decision
Orange Book leverage	Reduced after judgment
Generic entry risk	High
Biosimilar risk	Not applicable
Geographic scope	U.S. patent judgment; foreign rights not determined
Regulatory exclusivity	Separate from patent rights and dependent on FDA records
Litigation leverage	Limited against Hospira after affirmance

The judgment did not automatically invalidate foreign patents, international applications, or unrelated U.S. patents held by Belcher or other parties. Patent rights are jurisdiction-specific, and the decision directly resolved the asserted U.S. patent in the Delaware action.

What generic launch risks existed for Belcher’s epinephrine product?

The principal risk was loss of market exclusivity through an approved generic epinephrine injection. Once the patent barrier failed, Hospira could pursue FDA approval without waiting for the patent’s nominal expiration date.

Commercial consequences can include:

• Lower net prices;
• Pharmacy substitution;
• Hospital purchasing pressure;
• Formulary displacement;
• Reduced contracting leverage;
• Higher rebate requirements; and
• Revenue erosion for the branded epinephrine product.

The exposure is more acute for a product with limited differentiation from generic epinephrine injection. A formulation patent can protect a product’s commercial position only if the claims survive validity and enforceability challenges and if the product’s label and listing accurately align with the patent claims.

How does this case compare with other pharmaceutical patent litigation?

Belcher v. Hospira differs from a conventional active-ingredient patent case. The dispute did not concern a new molecular entity or a broad composition-of-matter patent. It concerned a formulation range around an established drug.

That distinction affects litigation strength:

Patent type	Typical strength	Belcher relevance
Composition of matter	Often strongest, broadest exclusion	Not at issue
Salt or polymorph	Variable; depends on unexpected properties	Not the principal issue
Formulation	Narrower and fact-intensive	Central to the case
Method of treatment	Depends on label and induced infringement	Not central
Manufacturing process	Can create supply-chain barriers	Not central
Device or delivery system	May protect a differentiated presentation	Not central

The case is a warning for companies relying on formulation patents to protect mature active ingredients. Claim scope, technical evidence, prosecution disclosure, and the relationship between regulatory submissions and patent prosecution can determine whether the patent provides meaningful commercial exclusivity.

What are the key business implications of the decision?

The decision has four main implications.

First, Hospira’s Paragraph IV strategy succeeded. The company challenged the patent before nominal expiry and obtained an appellate affirmance of invalidity and unenforceability.

Second, Belcher’s product protection depended heavily on a single formulation patent. That created concentration risk. When the patent failed, the litigation record did not identify a surviving patent that could preserve the same level of U.S. market protection.

Third, FDA communications became relevant to patent enforceability. Regulatory and patent teams must treat technical FDA correspondence as potentially material to prosecution.

Fourth, formulation patents require robust comparative data. Stability results must be tied directly to the claimed features, and the evidence must cover the full claim scope. Narrow numerical ranges are vulnerable if they appear to reflect routine optimization rather than a demonstrated technical breakthrough.

Key Takeaways

• Belcher Pharmaceuticals v. Hospira, Civil Action No. 1:19-cv-01854, involved a Paragraph IV challenge to Belcher’s epinephrine formulation patent.
• The patent at issue was U.S. Patent No. 9,283,197.
• The asserted claims covered epinephrine formulations with a defined pH range and sulfite component.
• The District of Delaware held the patent invalid for obviousness and unenforceable for inequitable conduct.
• The Federal Circuit affirmed the judgment in 2021.
• The case removed the principal U.S. patent barrier to Hospira’s proposed generic epinephrine product.
• The dispute involved generic competition, not biosimilar competition.
• The decision reduced Belcher’s formulation-based exclusivity and increased generic-entry risk.
• The ruling did not automatically resolve foreign patent rights or unrelated U.S. patents.
• FDA communications concerning formulation development can create patent-disclosure obligations when material to patentability.

FAQs

What drug was at issue in Belcher Pharmaceuticals v. Hospira?

The case involved epinephrine injection, a small-molecule injectable product used in emergency and cardiovascular treatment settings.

What was the patent number in Belcher v. Hospira?

The principal patent was U.S. Patent No. 9,283,197, titled “Pharmaceutical compositions of epinephrine.”

Did Belcher win its patent case against Hospira?

No. Belcher lost in the District of Delaware, and the Federal Circuit affirmed the judgment that the patent was invalid and unenforceable.

Did Hospira’s product qualify as a biosimilar?

No. Hospira’s product was a proposed generic drug subject to the ANDA and Hatch-Waxman framework.

What lesson does the case provide for pharmaceutical patent prosecution?

Companies should evaluate FDA communications, product-development records, and formulation data for patentability relevance and should preserve evidence linking claimed formulation parameters to unexpected technical results.

References

1. U.S. District Court for the District of Delaware. (2021). Belcher Pharmaceuticals, LLC v. Hospira, Inc., No. 1:19-cv-01854.
2. United States Court of Appeals for the Federal Circuit. (2021). Belcher Pharmaceuticals, LLC v. Hospira, Inc., 11 F.4th 1345.
3. United States Patent and Trademark Office. (2016). U.S. Patent No. 9,283,197: Pharmaceutical compositions of epinephrine.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.